Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Double-blind, Double-dummy, Placebo Controlled (With Rescue Medication), Multicenter Study to Evaluate the Efficacy and Safety of Fluticasone Furoate Inhalation Powder in the Treatment of Persistent Asthma in Adults and Adolescents.
Brief Summary: A randomised, double-blind, double-dummy, placebo controlled (with rescue medication), multicenter study to evaluate the efficacy and safety of Fluticasone Furoate inhalation powder in the treatment of persistent asthma in adults and adolescents.


Options:
A: Arm Label: Fluticasone Furoate OD and Placebo BID; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone furoate, Drug: Placebo | Arm Label: Fluticasone Propionate BID and Placebo OD; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone propionate, Drug: Placebo | Arm Label: Placebo only BID; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Fluticasone propionate; Assigned to Arm(s): Fluticasone Propionate BID and Placebo OD | Intervention Type: DRUG; Name: Fluticasone furoate; Assigned to Arm(s): Fluticasone Furoate OD and Placebo BID | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Fluticasone Furoate OD and Placebo BID, Fluticasone Propionate BID and Placebo OD, Placebo only BID
B: Arm Label: MF/F MDI 400/10 mcg BID; Type: EXPERIMENTAL; Interventions: Drug: Mometasone furoate/formoterol (MF/F) combination | Arm Label: MF/F MDI 200/10 mcg BID; Type: EXPERIMENTAL; Interventions: Drug: Mometasone furoate/formoterol (MF/F) combination | Arm Label: MF MDI 400 mcg BID; Type: EXPERIMENTAL; Interventions: Drug: Mometasone furoate MDI (MF MDI) | Arm Label: Formoterol MDI 10 mcg BID; Type: ACTIVE_COMPARATOR; Interventions: Drug: Formoterol MDI | Arm Label: Placebo MDI BID; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Mometasone furoate/formoterol (MF/F) combination; Assigned to Arm(s): MF/F MDI 400/10 mcg BID | Intervention Type: DRUG; Name: Mometasone furoate/formoterol (MF/F) combination; Assigned to Arm(s): MF/F MDI 200/10 mcg BID | Intervention Type: DRUG; Name: Mometasone furoate MDI (MF MDI); Assigned to Arm(s): MF MDI 400 mcg BID | Intervention Type: DRUG; Name: Formoterol MDI; Assigned to Arm(s): Formoterol MDI 10 mcg BID | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo MDI BID
C: Arm Label: GW685698X (fluticasone furoate) 100mcg Morning; Type: EXPERIMENTAL; Interventions: Drug: GW685698X (fluticasone furoate) 100mcg Morning | Arm Label: GW685698X (fluticasone furoate) 100mcg Evening; Type: EXPERIMENTAL; Interventions: Drug: GW685698X (fluticasone furoate) 100mcg Evening | Arm Label: GW685698X (fluticasone furoate) 250mcg Evening; Type: EXPERIMENTAL; Interventions: Drug: GW685698X (fluticasone furoate) 250mcg Evening | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: GW685698X (fluticasone furoate) 100mcg Morning, Drug: GW685698X (fluticasone furoate) 100mcg Evening, Drug: GW685698X (fluticasone furoate) 250mcg Evening, Drug: Placebo | Intervention Type: DRUG; Name: GW685698X (fluticasone furoate) 100mcg Morning; Assigned to Arm(s): GW685698X (fluticasone furoate) 100mcg Morning, Placebo | Intervention Type: DRUG; Name: GW685698X (fluticasone furoate) 100mcg Evening; Assigned to Arm(s): GW685698X (fluticasone furoate) 100mcg Evening, Placebo | Intervention Type: DRUG; Name: GW685698X (fluticasone furoate) 250mcg Evening; Assigned to Arm(s): GW685698X (fluticasone furoate) 250mcg Evening, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Fp MDPI 100 mcg; Type: EXPERIMENTAL; Interventions: Drug: Fp MDPI, Drug: albuterol/salbutamol HFA | Arm Label: FLOVENT HFA 110 mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: FLOVENT HFA, Drug: albuterol/salbutamol HFA | Arm Label: Fp MDPI 200 mcg; Type: EXPERIMENTAL; Interventions: Drug: Fp MDPI, Drug: albuterol/salbutamol HFA | Arm Label: FLOVENT HFA 220 mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: FLOVENT HFA, Drug: albuterol/salbutamol HFA | Arm Label: FS MDPI 100/12.5 mcg; Type: EXPERIMENTAL; Interventions: Drug: FS MDPI, Drug: albuterol/salbutamol HFA | Arm Label: ADVAIR DISKUS 250/50 mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: ADVAIR DISKUS, Drug: albuterol/salbutamol HFA | Arm Label: FS MDPI 200/12.5 mcg; Type: EXPERIMENTAL; Interventions: Drug: FS MDPI, Drug: albuterol/salbutamol HFA | Arm Label: ADVAIR DISKUS 500/50 mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: ADVAIR DISKUS, Drug: albuterol/salbutamol HFA | Intervention Type: DRUG; Name: Fp MDPI; Assigned to Arm(s): Fp MDPI 100 mcg, Fp MDPI 200 mcg | Intervention Type: DRUG; Name: FS MDPI; Assigned to Arm(s): FS MDPI 100/12.5 mcg, FS MDPI 200/12.5 mcg | Intervention Type: DRUG; Name: FLOVENT HFA; Assigned to Arm(s): FLOVENT HFA 110 mcg, FLOVENT HFA 220 mcg | Intervention Type: DRUG; Name: ADVAIR DISKUS; Assigned to Arm(s): ADVAIR DISKUS 250/50 mcg, ADVAIR DISKUS 500/50 mcg | Intervention Type: DRUG; Name: albuterol/salbutamol HFA; Assigned to Arm(s): ADVAIR DISKUS 250/50 mcg, ADVAIR DISKUS 500/50 mcg, FLOVENT HFA 110 mcg, FLOVENT HFA 220 mcg, FS MDPI 100/12.5 mcg, FS MDPI 200/12.5 mcg, Fp MDPI 100 mcg, Fp MDPI 200 mcg

Answer: A